메뉴 건너뛰기




Volumn 21, Issue 15, 2015, Pages 3372-3376

FDA approval summary: Ramucirumab for gastric cancer

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PLACEBO; RAMUCIRUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

EID: 84942879447     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0600     Document Type: Article
Times cited : (76)

References (9)
  • 2
    • 84966634048 scopus 로고    scopus 로고
    • [about 1 screen]. [cited 2014 Dec 2]
    • SEER Stat fact sheets: stomach cancer; [about 1 screen]. [cited 2014 Dec 2]. Available from: http://seer.cancer.gov/statfacts/html/stomach.html.
    • SEER Stat Fact Sheets: Stomach Cancer
  • 4
    • 77956262693 scopus 로고    scopus 로고
    • Trastuzumab in combination with chemotherapy versus chemotherapy alone for the treatment of HER-2 positive advanced gastric or gastrooesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial
    • Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for the treatment of HER-2 positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-97.
    • (2010) Lancet , vol.376 , pp. 687-697
    • Bang, Y.J.1    Van Cutsem, E.2    Feyereislova, A.3    Chung, H.C.4    Shen, L.5    Sawaki, A.6
  • 5
    • 80053573446 scopus 로고    scopus 로고
    • Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized, double-blind, placebo-controlled phase III study
    • Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011; 29: 3968-76.
    • (2011) J Clin Oncol , vol.29 , pp. 3968-3976
    • Ohtsu, A.1    Shah, M.A.2    Van Cutsem, E.3    Rha, S.Y.4    Sawaki, A.5    Park, S.R.6
  • 6
    • 69149102489 scopus 로고    scopus 로고
    • Is there a role for second-line chemotherapy in advanced gastric cancer?
    • Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in advanced gastric cancer? Lancet Oncol 2009; 10: 903-12.
    • (2009) Lancet Oncol , vol.10 , pp. 903-912
    • Wesolowski, R.1    Lee, C.2    Kim, R.3
  • 7
    • 84892852372 scopus 로고    scopus 로고
    • Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial
    • Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014; 383: 31-9.
    • (2014) Lancet , vol.383 , pp. 31-39
    • Fuchs, C.S.1    Tomasek, J.2    Yong, C.J.3    Dumitru, F.4    Passalacqua, R.5    Goswami, C.6
  • 8
    • 84908139963 scopus 로고    scopus 로고
    • Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial
    • Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014; 15: 1224-35.
    • (2014) Lancet Oncol , vol.15 , pp. 1224-1235
    • Wilke, H.1    Muro, K.2    Van Cutsem, E.3    Oh, S.C.4    Bodoky, G.5    Shimada, Y.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.